Evidence map›Paper›PMID 32829744›Full record

ArticleSexual health2020

Acceptability and feasibility of recruiting women to collect a self-administered vaginal swab at a pharmacy clinic for sexually transmissible infection screening.

C A Gaydos, M Barnes, J Holden, B Silver, R Smith, J Hardick, T C Quinn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sexual health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C A GaydosDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA; and Corresponding author. Email: cgaydos@jhmi.edu.
M BarnesDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA.
J HoldenDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA.
B SilverDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA.
R SmithDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA.
J HardickDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA.
T C QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, 211 Preclinical Teaching Building, Fisher Center, 725 North Wolfe Street, Baltimore, MD 21205, USA; and Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI William Owen Osburn · 2007 to 2026
$34.6M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeaeR01AI138978 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF · 2018 to 2021
$5.1M
NIAID NIH HHS R01 AI138978NIAID NIH HHS U01 AI068613NIAID NIH HHS UM1 AI068613NIBIB NIH HHS U54 EB007958
6 · The paper itself

Abstract

Willingness to self-collect vaginal swabs at a pharmacy clinic is of interest as a venue to increase sexually transmissible infections (STIs) screening for chlamydia, gonorrhoea and trichomonas. Women self-collected vaginal swabs at the pharmacy, completed questionnaires and received STI results within 2 h. Women with STIs were offered free treatment. A total of 313 of 777 (40.3%) women consented and prevalence for any STI was 3.9%. Questionnaires demonstrated acceptability for self-collection at the pharmacy, with 63% (95% CI 57.3-68) and 32.3% (95% CI 27.4-37.8) indicating they 'strongly agreed' or 'agreed' that they felt comfortable with pharmacy collection, respectively. Self-collected vaginal swabs for STI testing for women who were at a pharmacy were feasible and acceptable to women.

Indexed as

Patient Acceptance of Health CarePharmaciesVaginal SmearsAdultFeasibility StudiesFemaleHumansMass ScreeningMiddle AgedSexually Transmitted DiseasesSpecimen HandlingSurveys and QuestionnairesYoung Adult

Identifiers

PMID32829744
PMCPMC7995601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.